Poly(A) RT–PCR measurement of diagnostic genes in pancreatic juice in pancreatic cancer

M Oliveira-Cunha*, 1, RJ Byers2 and AK Siriwardena1

1Hepatobiliary Surgery Unit, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK; 2Histopathology Department, Manchester Royal Infirmary, Manchester, UK

BACKGROUND: The last decade has seen significant progress in understanding the molecular biology of pancreatic adenocarcinoma. There is now an urgent need to translate these molecular techniques to clinical practice in order to improve diagnosis and prediction of response to treatment. The objectives of this study are to utilise poly(A) RT–PCR to measure expression levels of diagnostic Indicator genes, selected from microarray studies, of RNA from intraoperatively sampled pancreatic ductal juice and to correlate these expression levels with those in matched pancreatic tissue resection samples.

METHODS: Intraoperative sampling of pancreatic juice and collection of matched tissue samples was undertaken in patients undergoing pancreaticoduodenectomy for suspected tumour. RNA was isolated and poly(A) PCR and real-time PCR used to measure expression levels of 30 genes. Spearman’s rank correlation test was used to examine the relationship of gene expression between pancreatic juice and tissue.

RESULTS: Of the 30 Indicator genes measured, just one, ANXA1, showed a significant correlation of expression level between pancreatic juice and tissue samples, whereas three genes, IGFBP3 (P < 0.035), PSCA (P < 0.001) and SPINK1 (P < 0.05), showed significantly different expression between cancerous and benign pancreatic tissue samples.

CONCLUSIONS: These results demonstrate that RNA analysis of pancreatic juice is feasible using the poly(A) cDNA technique, that correlation of gene expression exists between pancreatic juice and tissue for very few genes and that gene expression profiling can distinguish between benign and malignant pancreatic tissue. This indicates possible use of the technique for measurement of Indicator genes in pancreatic tissue for diagnosis of pancreatic cancer from very small tissue samples.

British Journal of Cancer (2011) 104, 514–519. doi:10.1038/sj.bjc.6606047 www.bjcancer.com

Published online 18 January 2011
© 2011 Cancer Research UK

Keywords: poly(A) cDNA; RT–PCR; quantitative RT–PCR; pancreatic cancer and gene expression in pancreatic cancer

Carcinoma of the pancreas (PC) is an aggressive disease and the fourth leading cause of cancer-related mortality in the Western world (Jemal et al., 2009). The 5-year survival rates for affected patients are a dismal 3%, emphasising the need for studies to better understand the molecular biology of pancreatic cancer and to translate this knowledge to clinical practice (Neoptolemos et al., 2001).

Increased knowledge of the molecular basis of cancer in general has led to a better understanding of the pathobiology of most cancers, with the possibility of improved diagnosis and development of novel treatments; this is also the case for pancreatic cancer. Recent advances in global gene expression profiling have provided molecular markers for cancer diagnosis, and there is a need to develop methods for their measurement in routine clinical samples.

Global cDNA amplification, by poly(A) PCR, allows marker genes to be detected at very low levels, improving sensitivity, while also providing an improved level of specificity through the ability to analyse multiple genes (Brady and Iscove, 1993; Sakhinia et al., 2005; Byers et al., 2008). Critically, global cDNA permits analysis of very small numbers of cells. This is of particular relevance in enabling measurement of gene expression profiles from cells isolated from pancreatic juice, providing a relatively noninvasive method for diagnosis (Oliveira-Cunha et al., 2010a).

Additionally, the poly(A) PCR method can produce an essentially permanent archive of representative cDNA suitable for screening with multiple gene-specific probes. Furthermore, the method is rapid (all samples can be prepared and screened within 48 h) and of particular importance for clinical use (Brady et al., 1995; Sakhinia et al., 2005; Oliveira-Cunha et al., 2010a, b).

This study explores the feasibility of gene expression profiling from RNA isolated from pancreatic ductal juice and tests the hypothesis that detection of gene signatures, the so-called Indicator genes, measured by globally amplified poly(A) cDNA in ductal juice from patients with pancreatic cancer will provide a high degree of correlation with Indicator genes detected by the same method in the tumour samples of the same patients. To test this hypothesis, RNA was extracted from pancreatic juice and tissue obtained intraoperatively from patients undergoing pancreaticoduodenectomy. Poly(A) PCR was used to globally amplify the RNA followed by measurement of the expression levels of Indicator genes by real-time PCR. The gene expression profiles
for pancreatic juice were then compared with those for the parallel pancreatic tissue samples.

**MATERIALS AND METHODS**

**Study population**

Pancreatic juice was collected by intraoperative aspiration of the main pancreatic duct in patients undergoing pancreaticoduodenectomy at Manchester Royal Infirmary between May 2007 and June 2009. For all patients a matched tissue sample from the main tumour was obtained from the fresh specimen under direct vision in the histopathology laboratory. The study protocol had local ethical committee approval and written informed consent was obtained from all patients. In all, 45 patients were included; sufficient pancreatic juice was obtained in 41 patients with matched pancreatic tissue/pancreatic juice in 34 of these patients. Histological analysis confirmed pancreatic/peripancreatic malignancy in 37 cases (11 ductal adenocarcinomas, 14 ampullary carcinomas, 3 cholangiocarcinomas, 4 intraductal papillary mucinous neoplasms (IPMNs), 2 neuroendocrine tumour, 2 mucinous cystic neoplasms (MCNs) and 1 acinar cell carcinoma). Of the non-cancer group, seven were chronic pancreatitis and one autoimmune pancreatitis. In the subset of 34 patients with matched pancreatic tissue and juice, the diagnoses were: 10 ductal adenocarcinomas, 12 ampullary carcinomas, 2 cholangiocarcinomas, 1 neuroendocrine tumour, 3 IPMNs, 1 MCN, 1 autoimmune pancreatitis and 4 chronic pancreatitis.

**Extraction of RNA and global amplification of polyadenylated mRNAs (poly(A)-RT–PCR)**

Isogen-LS (Wako, Osaka, Japan) was used in combination with RNeasy mini Kit (Qiagen, Crawley, UK) for total RNA extraction and purification from pancreatic juice. Total RNA from pancreatic tissue was extracted following the RNeasy kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Samples were then quantified using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) analysis and RNA integrity was checked by Agilent 2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany) according to the manufacturer’s instructions. The poly(A)-PCR method has three steps, namely poly(A) primed reverse transcription to produce a first-strand cDNA for each mRNA; polyadenylation of the first-strand cDNA, rendering it defined at both ends; and polymerase chain reaction using a poly(dt) primer, which anneals to the poly(A) site on the first-strand cDNA. We performed poly(A)-PCR on RNA isolated following standard published protocols.

**TaqMan real-time quantitative PCR**

TaqMan PCR primers and probes were designed for 30 Indicator genes that have previously been reported as overexpressed in pancreatic cancer together with two housekeeping genes (GAPDH and HPRT) using Custom TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA, USA); details of all primers and probes used are listed in Supplementary Table 1 online. The genes studied were selected after literature review of microarray data. The selected genes include a range of genes covering lineage markers, cell cycle markers and activation markers in order to maximise possibility of detection of genes that are overexpressed in pancreatic cancer, metastatic disease, ductal epithelial cells and chronic pancreatitis. All PCR primer pairs were designed for an mRNA sequence within 300 base pair (bp) of the poly(A) signal of each Indicator gene.

The real-time PCR reactions were performed in 96-well optical reaction plates, in a final volume of 25 μl, containing 12.5 μl of TaqMan Universal PCR Mastermix (Applied Biosystems), 1.25 μl of Custom TaqMan Gene Expression Assays Primers and probes (Applied Biosystems), 8.75 μl of UltraPure DEPC water (Invitrogen, Carlsbad, CA, USA) and 2.5 μl of cDNA. All samples were analysed using an ABI Prism 7900HT sequence detection system (Applied Biosystems).

Amplification plots indicating fluorescence intensity at each cycle were obtained from which Ct values were measured for each sample. PCRs were run in triplicates for each sample and Ct averages were obtained. The average Ct value for each gene for each patient was calculated from the triplicates, followed by normalisation to the average of the two housekeeping genes following the 2–ΔΔCt method (Livak and Schmittgen, 2001; Scheief et al, 2006; Yuan et al, 2008).

**Statistical analysis**

Statistical analyses were carried out using Excel (Microsoft, Redmond, WA, USA) and SPSS (Statistical Package for Social Sciences, Woking, Surrey, UK) version 17. Relative fold changes were calculated using the ΔΔCt method (Livak and Schmittgen, 2001; Scheief et al, 2006; Yuan et al, 2008).

The data were not normally distributed; therefore, nonparametric tests were used. Spearman’s rank correlation was used to examine the relationship between pancreatic juice and pancreatic tissue samples. Statistical analysis of the expression levels of the 30 Indicator genes in the benign and cancer groups was performed using the Mann–Whitney test, with a P-value of at least 0.05 for statistical significance. As the expression levels for all the genes fall across a wide range, the log10 scale was used to plot all values to aid visual comparison. The ranking of the expression levels of Indicator genes between samples was presented as the mean rank statistical difference. False discovery rate analysis was used to control for multiple comparisons. The q-value is defined to be the FDR analogue of the P-value and should be <0.05 to be considered significant.

**RESULTS**

**RNA extraction**

Total RNA was successfully extracted from all 41 samples of pancreatic juice and all 34 samples of pancreatic tissue. For pancreatic juice the median RNA yield was 68.45 ng μl–1 (range from 2.75 to 1418 ng μl–1, s.d. ± 268.3 ng μl–1). RNA quality, assessed by RNA integrity number (RIN), gave a median RIN of 5.5 (range from 1.9 to 10). Analysis of the RIN, purity ratios and gel electrophoretic results in combination demonstrated good-quality RNA in 25 cases and poor-quality RNA in 16 cases.

For pancreatic tissue, the median RNA yield was 132 ng μl–1 (range from 3.8 to 2594 ng μl–1, s.d. ± 643 ng μl–1). The median purity ratio 260/280 was 2.09 (range from 1.41 to 2.15, s.d. ± 0.19) for total RNA of pancreatic tissue.

**Poly(A) PCR**

Poly(A) cDNA was generated from mRNA extracted from all samples of pancreatic juice and tissue. The cDNA quantity, assessed by gel electrophoresis, generated from each sample, was highly reproducible over at least duplicate tests, demonstrating the reliability of the method.

**Real-time PCRs**

After real-time PCR, Ct values were obtained for each sample and gene. Samples were normalised according to Ct values of the average for both housekeeping gene in each sample. Figure 1 illustrates the median gene expression levels (median ΔCt values in logarithmic scale) of all genes tested.
Gene expression levels in pancreatic juice compared with pancreatic tissue samples

Median gene expression levels in pancreatic juice were similar to that in the corresponding resection specimen, with the exception of TFF2 and S100P. A statistically significant correlation was present for ANXA1 (P<0.043), MSLN (P<0.037) and PLAT (P<0.046). However, these P-values are results of multiple comparisons; therefore, false discovery rate (FDR) control was used for correction. The correlation coefficients are shown in Table 1; none of the 30 genes were significant by FDR at a q-value of <0.05.

As tumoral cells are shed into the pancreatic duct and juice in ductal adenocarcinoma, the number of malignant cells in pancreatic juice may be higher in these cases. For this reason, subgroup analysis of 30 Indicator genes using Spearman’s correlation was performed in the ductal adenocarcinoma samples (n = 11). Expression levels between pancreatic juice and tissue samples in ANXA1 gene were correlated with q-values <0.05, Q ≤0.002; the correlation coefficients are shown in Table 2.

Gene expression levels in pancreatic juice and tissue samples in pancreatic cancer compared with chronic pancreatitis

Mann–Whitney U-test did not identify any genes with statistically different expression between cancer and benign samples in pancreatic juice samples. Of the 30 Indicator genes studied in pancreatic tissue, only KLK3 was not expressed in pancreatic cancer or chronic pancreatitis samples. Mann–Whitney U test identified three genes, namely IGFBP3 (P<0.035), PSCA (P<0.001) and SPINK1 (P<0.055), with statistically different expression between cancerous and benign pancreatic tissue samples (Figure 2).

DISCUSSION

Use of gene expression profiles represents an innovative approach to cancer classification and prognostication and has been applied to an increasingly wide range of cancers. Measurement of these gene signatures by real-time PCR would enable translation to clinical use, whereas their analysis in pancreatic juice would allow noninvasive diagnosis and monitoring. This study tests whether these gene signatures can be identified in pancreatic ductal juice as this is a relatively easily accessible biological material. For the purposes of this study, we have compared gene signatures in ductal juice with those in the pancreatic tumour specimen in the same patient. As not all patients undergoing resection had adenocarcinoma, we have also examined for differences in gene expression profile between juice and pancreatic tissue in patients with either benign disease or cancer.

This study demonstrated that three genes, IGFBP3, SPINK1 and PSCA, can differentiate, in tissue samples, cancerous samples from benign samples (normal and chronic pancreatitis cases). It also

![Figure 1](Gene expression in 30 Indicator genes after normalisation to reference genes. This graph illustrates the median gene expression values (Ct values in log scale, after normalisation for GAPDH and PSM86) in pancreatic juice and tissue samples. Pancreatic juice and tissue were tested for 30 Indicator genes. The KLK3 gene was not expressed in any of the samples tested.)

Table 1 Spearman’s correlation coefficients of pancreatic juice vs pancreatic tissue

| Gene | Sig. (two-tailed) P-value | Q-value (FDR) | Gene | Sig. (two-tailed) P-value | Q-value (FDR) |
|------|--------------------------|--------------|------|--------------------------|--------------|
| CBP1 | 0.328                    | 0.791        | II8  | 0.355                    | 0.791        |
| TFF2 | 0.940                    | 0.971        | MSLN | 0.037*                   | 0.444        |
| EGFR | 0.946                    | 0.971        | NMU  | 0.229                    | 0.791        |
| IGFBP3 | 0.732                | 0.941        | NNMT | 0.639                    | 0.941        |
| AMACR | 0.770                   | 0.941        | POSTN | 0.528                   | 0.941        |
| ARMET | 0.772                   | 0.941        | SLPI  | 0.712                    | 0.941        |
| JAG1 | 0.874                    | 0.971        | CDH3  | 0.209                    | 0.941        |
| KRT7 | 0.228                    | 0.971        | GPRCSA | 0.560                   | 0.941        |
| MMP1 | 0.311                    | 0.791        | LCN2  | 0.176                    | 0.791        |
| MTA1 | 0.779                    | 0.941        | NQO1  | 0.639                    | 0.941        |
| NAME1 | 0.283                   | 0.791        | PLAT  | 0.046*                   | 0.444        |
| S100P | 0.479                   | 0.926        | PRSS2 | 0.311                    | 0.791        |
| SPINK1 | 0.885                 | 0.971        | PSCA  | 0.971                    | 0.971        |
| ANXA1 | 0.043*                  | 0.444        | TIMP1 | 0.105                    | 0.761        |
| CEACAM6 | 0.475                | 0.926        | KLK3  | Not expressed            | Not expressed |

Abbreviations: ANXA1 = annexin A1; ARMET = now called MANF, mesencephalic astrocyte-derived neurotrophic; AMACR = a-methylacyl-CoA racemase; CEACAM6 = carcinoembryonic antigen-related cell adhesion molecule 6; (non-specific cross reacting antigen); CDH3 = cadherin 3, type 1, P-cadherin (placental); CBP1 = carboxypeptidase B1; EGFR = epidermal growth factor receptor; FDR = false discovery rate; GPRCSA = G protein-coupled receptor family C, group5 member A factor; IL8 = interleukin 8; IGFBP3 = insulin-like growth factor binding protein 3; JAG1 = jagged 1; KLK3 = kallikrein-related peptidase 3; KRT7 = keratin 7; LCN2 = lipocalin 2; MSLN = mesothelin; MMP1 = matrix metallopeptidase 11; (stromelysin 3); MTA1 = metastasised associated 1; NQO1 = NAD(P)H dehydrogenase, quinone 1; NMU = neuromedin U; NNMT = nicotinamide N-methyltransferase; NME1 = non-metastatic cells 1, protein (NM23A) expressed in; POSTN = periostin; osteoblast specific factor; PLAT = plasminogen activator, tissue; PRSS2 = protease, serine 2 (trypsin 2); PSCA = prostate stem cell antigen; S100P = S100 calcium binding protein P; SPINK1 = serine peptidase inhibitor, Kazal type 1; SLPI = secretory leukocyte peptidase inhibitor; TFF2 = trefoil factor 2; TIMP1 = TIMP metallopeptidase inhibitor 1. *P<0.05.
Several studies demonstrated that overexpression of Annexin I altered expression, death and the hypothalamic–pituitary axis. The molecular mechanisms and the clinical significance of Annexin I altered expression in malignancies still remain a debate. Results from several studies demonstrated that overexpression of Annexin I is a frequent event in pancreatic cancer, which may be one of the factors associated with malignant transformation, de-differentiation and poor prognosis of pancreatic cancer (Han et al., 2002; Iacobuzio-Donahue et al., 2002; Iacobuzio-Donahue et al., 2003a, b; Bai et al., 2004; Grutzmann et al., 2004).

The lack of significant statistical correlation between gene expression in pancreatic juice and tissue samples for the majority of the Indicator genes may be because of the small amount of RNA in pancreatic juice and tissue samples when ductal adenocarcinoma samples were analysed as a discrete cohort. Annexin I belongs to a family of Ca\(^{2+}\)-dependent phospholipid-binding proteins with phospholipase A\(_2\) inhibitory activity. Annexin I is a steroid-regulated protein and thus implicated in some actions of glucocorticoids, including inhibition of cell proliferation, anti-inflammatory effects, the regulation of cell migration, differentiation, death and the hypothalamic–pituitary axis. The molecular mechanisms and the clinical significance of annexin I altered expression in malignancies still remain a debate. Results from several studies demonstrated that overexpression of Annexin I is a frequent event in pancreatic cancer, which may be one of the factors associated with malignant transformation, de-differentiation and poor prognosis of pancreatic cancer (Han et al., 2002; Iacobuzio-Donahue et al., 2002; Iacobuzio-Donahue et al., 2003a, b; Bai et al., 2004; Grutzmann et al., 2004).

The lack of significant statistical correlation between gene expression in pancreatic juice and tissue samples for the majority of the Indicator genes may be because of the small amount of RNA in pancreatic juice and to RNA degradation by RNases, which could affect certain transcripts more than others. Additionally, there is no clear evidence as to whether the origin of the differentially expressed mRNAs in the pancreatic juice is from secreted RNA or released tumour cells, and the different mRNA levels found in the pancreatic juice compared with the solid tumour may merely reflect a sub-population of mRNAs that are preferentially secreted or cells that are preferentially shed that are nevertheless indicative of pancreatic cancer (Tomlinson and Korc, 2006). In addition, the mRNAs measured in pancreatic juice may reflect cells involved in inflammatory responses.

Three genes, IGFBP3, SPINK1 and PSCA, showed differential expression between cancerous and benign samples. The IGFBP3 is a gene member of the insulin-like growth factor binding protein (IGFBP) family, and encodes a protein with an IGFBP domain and a thyroglobulin type-I domain (Hansel et al., 2004). Insulin-like...
growth factors (IGFs) are multifunctional peptides that regulate cell proliferation, differentiation and apoptosis elements important in carcinogenesis. IGFBP-3 is the main binding protein of IGF-I, and it circulates in the plasma, prolonging the half-life of IGFs and altering their interaction with cell surface receptors (Hansel et al., 2004; Renehan et al., 2004). In agreement with previous microarray studies, the present study has demonstrated that IGFBP3 is overexpressed in pancreatic cancer and can differentiate cancerous from benign tissue (Iacobuzio-Donahue et al., 2002; Logsdon et al., 2003; Iacobuzio-Donahue et al., 2003a; Grutzmann et al., 2004; Missiaglia et al., 2004; Laurell et al., 2006).

The SPINK1 gene encodes pancreatic secretory trypsin inhibitor (PSTI) and tumour-associated trypsin inhibitor (TATI), which is secreted from ductal cells into pancreatic juice. PSTI is thought to function in the prevention of trypsin-catalysed premature activation of zymogens within the pancreas and the pancreatic duct. The serum levels of PSTI increase in association with severe inflammatory association, tissue damage and major surgery, all of which suggest that PSTI has a role in the acute-phase reaction (Graf and Bimmer, 2006; Paju and Stenman, 2006). The SPINK1 gene is normally not expressed outside of the pancreas, but its expression has been demonstrated to be elevated in pancreatic cancer (Friess et al., 2001; Iacobuzio-Donahue et al., 2002; Iacobuzio-Donahue et al., 2003a; Grutzmann et al., 2004; Fukushima et al., 2005), whereas the present study demonstrated that SPINK1 is highly expressed in normal pancreatic tissue compared with pancreatic cancer.

The PSAC gene encodes a glycoprotein that is anchored to the cell membrane. Real-time PCR and immunohistochemistry studies have demonstrated that PSAC has a limited normal tissue distribution and is most strongly expressed in cells of the prostate (Reiter et al., 1998). Recently, immunohistochemistry and northern blot studies revealed that normal pancreatic tissue does not express PSAC, with the exception of a single case of atrophic pancreatic ducts (Reiter et al., 1998; Argani et al., 2001). This study has demonstrated that PSAC is overexpressed in pancreatic cancer and poorly expressed in normal pancreas and chronic pancreatitis, and similar results have been found in microarray and real-time studies (Argani et al., 2001; Ryu et al., 2002; Missiaglia et al., 2004; Grubbs et al., 2006).

RNA extraction and quality is a critical step in gene expression studies. To date, RNA extraction from pancreatic tissue and juice processing has not been standardised, leading to unanswered concerns of how to best store the collected specimen and maintain reproducibility. The development of effective and reproducible RNA isolation techniques depends on inhibition of contaminating RNases, enrichment of messenger RNA species and elimination of contaminating DNA (Kiba et al., 2007). In this study, to limit RNA degradation, pancreatic juice and tissue were placed immediately into an RNase inhibitor solution. To assure good RNA quality, four different methods of RNA extraction were tested and the method that generated the highest purity ratio (A260/A280 and A230/A260) was selected. Of particular relevance to clinical practice is the utility to work with small index sample volumes and to generate results in a short time frame. The results indicate that ANXA1 in pancreatic ductal juice has translational potential as a marker of pancreatic cancer. Furthermore, the differential expression patterns of SPINK1, PSAC and IGFBP3 may be of value in the differentiation of pancreatic cancer from chronic pancreatitis.

Conflict of interest
The authors declare no conflict of interest.

Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc)

REFERENCES
Argani P, Rosty C, Reiter RE, Wilzentz RE, Murugesan SR, Leach SD, Ryu B, Skinner HG, Goggins M, Jaffe EM, Yeo CJ, Cameron JL, Kern SE, Hruban RH (2001) Identification of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res 61: 4320–4324
Bai XF, Xi GQ, Zhao P, Liu SM, Wang HX, Guo B, Zhou LP, Liu F, Zhang JS, Wang K, Xie YQ, Shao YF, Zhao XH (2004) Overexpression of annexin 1 in pancreatic cancer and its clinical significance. World J Gastroenterol 10: 1466–1470
Brady G, Bill E, Knox J, Hoang T, Kirsch IR, Voura EB, Hawley RG, Cumming R, Buchwald M, Siminovich K (1995) Analysis of gene expression in a complex differentiation hierarchy by global amplification of cDNA from single cells. Curr Biol 5: 909–922
Brady G, Iscove NN (1993) Construction of cDNA libraries from single cells. Methods Enzymol 225: 611–623
Byers RJ, Sakkath E, Joseph P, Glennie C, Hoyland JA, Menasce LP, Radford JA, Illidge T (2008) Clinical quantitation of immune signature in follicular lymphoma by RT–PCR-based gene expression profiling. Blood 111: 4764–4770
Friess H, Ding J, Kleef J, Liao Q, Berberat PO, Hammer J, Buchler MW (2001) Identification of disease-specific genes in chronic pancreatitis using DNA array technology. Ann Surg 234: 769–778; discussion 778–779
Fukushima N, Koopmann J, Sato N, Prasad N, Carvalho R, Leach SD, Hruban RH, Goggins M (2005) Gene expression alterations in the non-neoplastic parenchyma adjacent to infiltrating pancreatic ductal adenocarcinoma. Mod Pathol 18: 779–787
Graf R, Bimmer D (2006) Biochemistry and biology of SPINK-PSTI and monitor peptide. Endocrinol Metab Clin North Am 35: 333–343, ix
Missiaglia E, Kalthoff H, Kremer B, Kloppe L, Cremer N, Kloppe G, Saeger HD (2004) Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. Neoplasia 6: 611–622
Han H, Bears DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD (2002) Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 62: 2890–2896
Hansel D, Rahman A, House MA, Ashfaq R, Berg K, Yeo C, Maitra A (2004) Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms. Clin Cancer Res 10: 6152–6158

© 2011 Cancer Research UK
Iacobuzio-Donahue C, Maitra A, Shen-Ong O, Van Heek T, Ashfaq R, Meyer R, Walter K, Berg K, Hollingsworth M, Cameron J, Yeo C, Kern S, Goggins M, Hruban R (2002) Discovery of novel tumour markers of pancreatic cancer using global gene expression technology. Am J Pathol 160: 1239–1249

Iacobuzio-Donahue CA, Ashfaq R, Maitra A, Adsay NV, Shen-Ong GL, Berg K, Hollingsworth MA, Cameron JL, Yeo CJ, Kern SE, Goggins M, Hruban RH (2003a) Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 63: 8614–8622

Iacobuzio-Donahue CA, Maitra A, Olsen M, Lowe AW, van Heek NT, Roesty C, Walter K, Sato N, Parker A, Ashfaq R, Jaffee E, Ryu B, Jones J, Edleman JB, Yeo CJ, Cameron JL, Kern SE, Hruban RH, Brown PO, Goggins M (2003b) Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol 162: 1151–1162

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4): 225–249

Kiba T, Kintaka Y, Nakada E, Suzuki Y, Inoue S, Ishigaki Y (2007) High-quality RNA extraction from rat pancreas for microarray analysis. Pancreas 35: 98–100

Laurell H, Bouisson M, Berthelemy P, Rochaix P, Dejanne S, Besse P, Susini C, Pradayrol L, Vaysse N, Buscail L (2006) Identification of biomarkers of human pancreatic adenocarcinomas by expression profiling and validation with gene expression analysis in endoscopic ultrasound-guided fine needle aspiration samples. World J Gastroenterol 12: 3344–3351

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402–408

Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK, Giordano TJ, Misek DE, Kuick R, Hanash S (2003) Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 63: 2649–2657

Missiaglia E, Blaveri E, Terris B, Wang YH, Costello E, Neoptolemos JP, Crnogorac-Jurcevic T, Lemoine NR (2004) Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis. Int J Cancer 112: 100–112

Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pedzeroli P, Derivenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Buchler MW (2001) Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 358: 1576–1585

Oliveira-Cunha M, Byers RJ, Siriwardena AK (2010a) Poly(adenylic acid) complementary DNA real-time polymerase chain reaction in pancreatic ductal juice in patients undergoing pancreaticoduodenectomy. Pancreas 39: 171–174

Oliveira-Cunha M, Siriwardena AK, Byers RJ (2010b) Poly(A) cDNA real-time PCR for indicator gene measurement in cancer. Methods Mol Biol 630: 13–32

Paju A, Stenman UH (2006) Biochemistry and clinical role of trypsinogens and pancreatic secretory trypsin inhibitor. Crit Rev Clin Lab Sci 43: 103–142

Reiter RE, Gu Z, Watabe T, Thomas G, Szegedi K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, Loda M, Witte ON (1998) Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 95: 1735–1740

Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363: 1346–1353

Rubie C, Kempf K, Hans J, Su T, Tilton B, Georg T, Brittner B, Ludwig B, Schilling M (2005) Housekeeping gene variability in normal and cancerous colorectal, pancreatic, esophageal, gastric and hepatic tissues. Mol Cell Probes 19: 101–109

Ryu B, Jones J, Blades NJ, Parmigiani G, Hollingsworth MA, Hruban RH, Kern SE (2002) Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res 62: 819–826

Sakhinia E, Faranghpour M, Liu Yin JA, Brady G, Hoyland JA, Byers RJ (2005) Routine expression profiling of microarray gene signatures in acute leukaemia by real-time PCR of human bone marrow. Br J Haematol 130: 233–248

Schefe JH, Lehmann KE, Buschmann IR, Unger T, Funke-Kaiser H (2006) Quantitative real-time RT-PCR data analysis: current concepts and the novel ‘gene expression’s CT difference’ formula. J Mol Med 84: 901–910

Tomlinson CR, Korc M (2006) Squeezing data from pancreatic juice. Cancer Biol Ther 5: 1390–1391

Yuan JS, Wang D, Stewart Jr CN (2008) Statistical methods for efficiency adjusted real-time PCR quantification. Biotechnol J 3: 112–123